A summary of daily biopharma industry news regarding the novel coronavirus trending on March 27, 2020, with the FDA now working with 220 test developers.
Sanofi Pasteur, the vaccines business for French pharma giant Sanofi, and Massachusetts-based Translate Bio have partnered to develop a novel messenger RNA (mRNA) vaccine for COVID-19.
A recap of business developments from life sciences companies around the world, including U.K.-based Vaccitech Limited and the University of Oxford touting positive safety and efficacy trends in a mid-stage prostate cancer study.
As the number of diagnosed cases of COVID-19 continues to increase across the globe and more and more governments are urging citizens to self-quarantine, the pharmaceutical and life sciences industry continues to work toward the development of a vaccine and therapies for the respiratory infection that was declared a pandemic by the World Health Organization.
U.S. drugmaker Pfizer Inc. signed a deal with Germany’s BioNTech SE to co-develop a potential vaccine for the coronavirus using BioNTech’s mRNA-based drug development platform, the companies said on Tuesday.
Inside the United States, the first clinical trial for a vaccine to the novel coronavirus that causes COVID-19 begins today. The mRNA-1273 vaccine is being developed by Moderna Therapeutics with the National Institute of Allergy and Infectious Disease (NIAID).
The World Health Organization (WHO) gave the coronavirus that began in Wuhan, China, an official name: COVID-19. The most recent figures indicate there are more than 45,000 infections worldwide and the virus has killed more than 1,100 people.
China’s National Health Commission stated today that the coronavirus has infected 5,974 individuals, resulting in 132 deaths and 103 people being cured.
Cambridge, Mass.-based Moderna announced the publication of results from two Phase I clinical trials of mRNA vaccines against two strains of influenza, H10N8 and H7N0.
